63 related articles for article (PubMed ID: 27486081)
1. Quantitative Structure-Activity Relationship Analysis and a Combined Ligand-Based/Structure-Based Virtual Screening Study for Glycogen Synthase Kinase-3.
Fu G; Liu S; Nan X; Dale OR; Zhao Z; Chen Y; Wilkins DE; Manly SP; Cutler SJ; Doerksen RJ
Mol Inform; 2014 Sep; 33(9):627-40. PubMed ID: 27486081
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore Modeling, Ensemble Docking, Virtual Screening, and Biological Evaluation on Glycogen Synthase Kinase-3β.
Fu G; Sivaprakasam P; Dale OR; Manly SP; Cutler SJ; Doerksen RJ
Mol Inform; 2014 Sep; 33(9):610-26. PubMed ID: 27486080
[TBL] [Abstract][Full Text] [Related]
3. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
4. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors.
Polgár T; Baki A; Szendrei GI; Keseru GM
J Med Chem; 2005 Dec; 48(25):7946-59. PubMed ID: 16335919
[TBL] [Abstract][Full Text] [Related]
5. Novel GSK-3beta inhibitors from sequential virtual screening.
Kim HJ; Choo H; Cho YS; No KT; Pae AN
Bioorg Med Chem; 2008 Jan; 16(2):636-43. PubMed ID: 18006321
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Discovery of 1H-Indazole-3-carboxamides as a Novel Structural Class of Human GSK-3 Inhibitors.
Ombrato R; Cazzolla N; Mancini F; Mangano G
J Chem Inf Model; 2015 Dec; 55(12):2540-51. PubMed ID: 26600430
[TBL] [Abstract][Full Text] [Related]
9. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β.
Mishra P; Kesar S; Paliwal SK; Chauhan M; Madan K
Cent Nerv Syst Agents Med Chem; 2018; 18(2):150-158. PubMed ID: 29848281
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X
J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001
[TBL] [Abstract][Full Text] [Related]
11. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR for GSK-3beta inhibition by indirubin analogues.
Zhang N; Jiang Y; Zou J; Zhang B; Jin H; Wang Y; Yu Q
Eur J Med Chem; 2006 Mar; 41(3):373-8. PubMed ID: 16442187
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel GSK-3β Inhibitors Using Pharmacophore and Virtual Screening Studies.
Balakrishnan N; Raj JS; Kandakatla N
Interdiscip Sci; 2016 Sep; 8(3):303-11. PubMed ID: 26298578
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
Khanfar MA; Hill RA; Kaddoumi A; El Sayed KA
J Med Chem; 2010 Dec; 53(24):8534-45. PubMed ID: 21082766
[TBL] [Abstract][Full Text] [Related]
15. Feature selection and linear/nonlinear regression methods for the accurate prediction of glycogen synthase kinase-3beta inhibitory activities.
Goodarzi M; Freitas MP; Jensen R
J Chem Inf Model; 2009 Apr; 49(4):824-32. PubMed ID: 19338295
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.
Crisan L; Avram S; Pacureanu L
Mol Divers; 2017 May; 21(2):385-405. PubMed ID: 28108896
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
19.
Emmerich TD; Hayes JM
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242443
[TBL] [Abstract][Full Text] [Related]
20. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]